ABL Diagnostics and CDL Pharma secure a multi year renewal of clinical services with a long standing Pharma partner

The multi‑year renewal strengthens ABL’s integrated platform, improving revenue visibility and supporting the Group’s ...

ABL Diagnostics Strengthens Strategic Supplier Agreements to Support Accelerated Growth

The renewed and expanded agreements provide improved commercial conditions, including more competitive pricing, optimized contractual terms, and enhanced supply security. These improvements will ...

All Invest Securities Flash Update to the Equity Research Coverage of ABL Diagnostics (For Professional Investors)

Strong Buy reiterated with a €8.37 target price following the 21 January 2026 Flash; last close on 22 January 2026: ...

ABL Diagnostics Update Regarding Non-Binding Letter of Intent

ABL Diagnostics S.A. (Euronext: ABLD – ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological Laboratories S.A. ( ...
Morningstar

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...
Seeking Alpha

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this ...